Protein Summary
Isoform 1: Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro) (PubMed:11148210). Does not bind acetyl-CoA and does not have histone acetyltransferase activity (PubMed:24088714). Isoform 3: Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as substrate but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro), but has about six times lower specific activity than isoform 1. The dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) addition and removal on serine and threonine residues is catalyzed by OGT (MIM 300255), which adds O-GlcNAc, and MGEA5, a glycosidase that removes O-GlcNAc modifications (Gao et al., 2001 [PubMed 11148210]).[supplied by OMIM, Mar 2008]
- ENST00000357797
- ENSP00000350445
- ENSG00000198408
- ENST00000361464
- ENSP00000354850
- ENST00000370094
- ENSP00000359112
- ENST00000439817
- ENSP00000409973
- HEXC
- KIAA0679
- MEA5
- MGEA5
- MEA5
- MGEA5
- NCOAT
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0.99 | ||
transcription factor perturbation | 0.94 | ||
transcription factor binding site profile | 0.89 | ||
kinase perturbation | 0.84 | ||
disease perturbation | 0.83 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2724.97 (req: < 5)
Gene RIFs: 41 (req: <= 3)
Antibodies: 159 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2724.97 (req: >= 5)
Gene RIFs: 41 (req: > 3)
Antibodies: 159 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 11
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 192
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0